* Infigen Inc., of DeForest, Wis., and Pharming Holding N.V., of Leiden, the Netherlands, formed a strategic partnership that combines elements of each company's technology in order to produce human therapeutics from the milk of transgenic cattle. Pharming will make an equity investment, provide research and devleopment funding, and pay milestone payments and royalties, if any. Infigen also has manufacturing rights. Infigen is a unit of ABS Global Inc., also of DeForest.
* Trimeris Inc., of Durham, N.C., initiated a 32-patient Phase II trial for T-20, an antiviral, fusion-inhibiting drug designed to block HIV infection. The trial will enroll HIV- infected patients who have failed existing triple combination therapy, and is designed to assess safety, plasma pharmacokinetics and antiviral activity of multiple ascending doses of T-20 monotherapy given by continuous subcutaneous infusion.
* Celgene Corp., of Warren, N.J., completed the $15 million sale of its Chiral Intermediate Business to Cambrex Corp., of East Rutherford, N.J. The acquisition provides Cambrex with Celgene's enzymatic technology for the production of chirally pure products for the pharmaceutical industry, a pipeline of products, and the equipment and personnel associated with the business.